Amphastar Pharmaceuticals, Inc. (AMPH) News
Follow Amphastar Pharmaceuticals, Inc. (AMPH) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 11 public stories across 8 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Amphastar Pharmaceuticals Reports Quarterly Results
The company reported results for the quarter ended September 30. The supplied summary contains no financial figures.
EQUITY | Nov 06, 2026, 01:04 AM UTC
L
Amphastar Pharmaceuticals 3Q 2026: Revenue $207.61M, EPS $0.87 — 10-Q Summary
Amphastar’s third-quarter revenue and earnings increased year over year. Higher BAQSIMI, Primatene MIST and lidocaine sales, new ipratropium bromide sales, and growth in other products outweighed declines in epinephrine
EARNINGS | Nov 05, 2026, 09:43 PM UTC
L
Amphastar Pharmaceuticals 3Q Rev $207.6M >AMPH
Amphastar Pharmaceuticals 3Q Rev $207.6M >AMPH
EQUITY | Nov 05, 2026, 09:11 PM UTC
M
Amphastar strategy targets branded and biosimilar growth through 2027
Management outlined a strategy centered on branded and complex generics, with BAQSIMI and new biosimilars aimed to drive near-term growth. Operational improvements and pipeline expansion target margin gains and revenue d
EQUITY | Sep 08, 2026, 09:57 PM UTC
M
AMPH strategy targets BAQSIMI and pipeline launches through 2026
AMPH management outlined a branded and complex generics strategy, citing BAQSIMI and new pipeline launches for mid to high single-digit revenue growth through 2026. Operational improvements and targeted R&D investments a
EQUITY | Sep 08, 2026, 09:32 PM UTC
L
AMPH: Robust R&D and a proprietary-focused pipeline drive growth, anchored by BAQSIMI® and Primatene MIST®
A fully integrated model and strong R&D investment have driven robust revenue and margin growth, with a pipeline shifting toward proprietary and biosimilar products. Key assets like BAQSIMI® and Primatene MIST® anchor co
EQUITY | Sep 08, 2026, 12:21 PM UTC
L
AMPH - Amphastar Pharmaceuticals to Present at the Wells Fargo 21st Annual Healthcare Conference
AMPH - Amphastar Pharmaceuticals to Present at the Wells Fargo 21st Annual Healthcare Conference
EQUITY | Sep 01, 2026, 10:01 AM UTC
L
AMPH AMPH - Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 6, 2026
AMPH AMPH - Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 6, 2026
EARNINGS | Jul 29, 2026, 10:00 AM UTC
L
Amphastar Unit Receives US FDA Warning Letter on Violations at California Facility
() -- Amphastar Pharmaceuticals (AMPH) unit International Medication Systems has received a warning letter from the US Food and Drug Administration on violations at its drug manufacturing facility in South El Monte, Cali
REGULATION | Jul 08, 2026, 11:04 AM UTC
L
WHO Director-General Ghebreyesus Says He Considers The Cruise Ship-Linked Hantavirus Outbreak To Be Over
WHO Director-General Ghebreyesus Says He Considers The Cruise Ship-Linked Hantavirus Outbreak To Be Over
EQUITY | Jul 02, 2026, 01:18 PM UTC
H
Crude Oil Gains 2%; Comcast Shares Spike Higher
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 200 points on Monday. The Dow traded up 0.44% to 52,105.66 while the NASDAQ rose 1.33% to 25,634.54. The S&P 500 also rose, gai
CENTRAL_BANK | Jun 29, 2026, 04:30 PM UTC